Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
← catalyst calendarNCT07679893 · readout in 529 d
Sponsored by Mannkind Corporation (industry) · MNKD — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
210estimated
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-30 | estimated | When the study began enrolling |
| Primary completion | 2028-01-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
- Drug: Nintedanib Dry Powder Inhalation
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFSafety and Efficacy
measured From enrollment to the end of randomized treatment at 12 weeks
Events of clinical bronchospasm
measured From enrollment to the end of open-label treatment at 36 weeks
FEV1 change
measured From enrollment to the end of open-label treatment at 36 weeks
Spirometry Change
measured enrollment to end of open label at 36 weeks
Study Drug Discontinuation
measured From enrollment to the end of open-label treatment at 36 weeks
Study Drug Dose Reductions
measured From enrollment to the end of open-label treatment at 36 weeks
Adverse Events
measured From enrollment to the end of open-label treatment at 36 weeks
Related Adverse Events
measured From enrollment to the end of open-label treatment at 36 weeks
Serious Adverse Events
measured From enrollment to the end of open-label treatment at 36 weeks
Permalink · MNKD's whole pipeline · Catalyst calendar · Every registered study · What changed